The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.
|Slideshows|April 4, 2017
IBIA 2017: Repercussions of TBI
Author(s)Samantha J. Peterson
Research presented at IBIA 2017 looked at risk behavior in adolescents, return to work, and maladaptive emotion regulation following TBI.
Advertisement
Research from the International Brain Injury Association’s World Congress examined various consequences of TBI. Studies included a possible link between childhood TBI and later risk behavior, completeness of return to work following mild TBI, and associations between TBI, PTSD, and maladaptive emotion regulation.
Advertisement
Related to this article
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is clinical trial results in Alzheimer disease!
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
One-year KYSA-6 data showed KYV-101, a CD19 CAR T-cell therapy, produced durable, drug-free responses in generalized myasthenia gravis.
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Azetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points
2
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
3
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5